And Sucampo Pharma Americas.

Additional data in lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting Sucampo Pharma Europe, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of Sucampo Pharmaceuticals, Inc. The info presented reflect additional analyses of already disclosed stage 2 and phase 3 clinical trials of lubiprostone in sufferers with chronic idiopathic constipation and in patients diagnosed with or reporting irritable bowel syndrome with constipation . Related StoriesExpectant mothers encouraged to consume balanced diet to reduce weight problems risk in unborn childLoyola gastroenterologist provides tips to IBS individuals for healthful livingNew capsule type of FMT raises expectations for dealing with C. Difficile infectionOverall, the data analyses demonstrated that, in these trials, lubiprostone achieved a statistically significant response in sufferers with IBS-C as compared to placebo individuals in a variety of symptomatic endpoints; demonstrated long-term efficacy via an general improvement in constipation severity for up to 12 weeks in adult patients regardless of age, gender or race; and achieved a significant response among refractory constipation sufferers when compared with placebo.Trish has generated a career around this intention, along with providing employment and business opportunities to other people who share her vision. Some ACC associates will receive a claims-free credit based also on the practice location. Related StoriesJohns Hopkins experts present new healthcare suggestions from American Center Association MeetingPeople with high fitness levels in midlife possess lower annual healthcare costs after age 65Drinking one 16-ounce energy drink may increase risk of cardiovascular events in young adults We are delighted that the ACC provides solely endorsed The Doctors Company mainly because its medical liability insurance company, said Richard E.